Literature DB >> 21619937

NSAIDs vs acetaminophen in knee and hip osteoarthritis: a systematic review regarding heterogeneity influencing the outcomes.

S P J Verkleij1, P A J Luijsterburg, A M Bohnen, B W Koes, S M A Bierma-Zeinstra.   

Abstract

OBJECTIVE: To identify sources of heterogeneity (statistical, methodological, and clinical) in studies evaluating non-steroidal anti-inflammatory drugs (NSAIDs) vs acetaminophen in patients with knee and hip osteoarthritis (OA) to elucidate variations in outcomes.
METHOD: A database search (1966 to January 2010) was made for (randomized) controlled trials ((R)CTs) comparing NSAIDs vs acetaminophen in knee and hip OA. Extracted data included baseline demographic/clinical characteristics, outcomes at follow-up, and characteristics of study design. Heterogeneity was examined with subgroup analyses by exploring changes in effect size and with I(2) of Higgins. Pain measures were expressed as standardized mean differences.
RESULTS: 15 RCTs, including 21 comparisons of NSAIDs and acetaminophen were included. Statistical heterogeneity was absent (Cochran's Q-test=14.11; I(2)=0; P=0.78). Moderate clinical heterogeneity was found for comparisons which included both hip and knee OA vs knee OA only (I(2)=51; P=0.09). NSAIDs seemed slightly more effective than acetaminophen if more patients with hip OA were included. However, the pooled effect sizes of comparisons with knee OA vs both knee and hip OA are equal. Low clinical heterogeneity was found for comparisons with low dosage of acetaminophen, normal dosage of NSAIDs, and moderate pain intensity at baseline. Low methodological heterogeneity was found for comparisons with a short duration.
CONCLUSION: Future trials should present the results of hip and knee OA separately, as moderate clinical heterogeneity was found. There might be differences in effectiveness of NSAIDs vs acetaminophen in patients with hip vs knee OA. No significant methodological and statistical heterogeneity was found in studies evaluating NSAIDs vs acetaminophen.
Copyright © 2011 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21619937     DOI: 10.1016/j.joca.2011.04.013

Source DB:  PubMed          Journal:  Osteoarthritis Cartilage        ISSN: 1063-4584            Impact factor:   6.576


  6 in total

1.  The Efficacy of a Lateral Wedge Insole for Painful Medial Knee Osteoarthritis After Prescreening: A Randomized Clinical Trial.

Authors:  David T Felson; Matthew Parkes; Suzanne Carter; Anmin Liu; Michael J Callaghan; Richard Hodgson; Michael Bowes; Richard K Jones
Journal:  Arthritis Rheumatol       Date:  2019-04-08       Impact factor: 10.995

2.  Mefenamic acid decreases inflammation but not joint lesions in experimental osteoarthritis.

Authors:  Grazielle C Aguiar; Celso M Queiroz-Junior; Giovana L Sitta; Flávio A Amaral; Mauro M Teixeira; Marcelo V Caliari; Anderson J Ferreira
Journal:  Int J Exp Pathol       Date:  2016-12       Impact factor: 1.925

3.  Emerging Treatment Models in Rheumatology: Challenges for Osteoarthritis Trials.

Authors:  David T Felson; Tuhina Neogi
Journal:  Arthritis Rheumatol       Date:  2018-06-06       Impact factor: 10.995

Review 4.  Comparative pain reduction of oral non-steroidal anti-inflammatory drugs and opioids for knee osteoarthritis: systematic analytic review.

Authors:  S R Smith; B R Deshpande; J E Collins; J N Katz; E Losina
Journal:  Osteoarthritis Cartilage       Date:  2016-02-01       Impact factor: 6.576

5.  The Clinical Efficacy and Safety of the Sahastara Remedy versus Diclofenac in the Treatment of Osteoarthritis of the Knee: A Double-Blind, Randomized, and Controlled Trial.

Authors:  Piya Pinsornsak; Puritat Kanokkangsadal; Arunporn Itharat
Journal:  Evid Based Complement Alternat Med       Date:  2015-02-15       Impact factor: 2.629

6.  Safe prescribing of non-steroidal anti-inflammatory drugs in patients with osteoarthritis--an expert consensus addressing benefits as well as gastrointestinal and cardiovascular risks.

Authors:  Carmelo Scarpignato; Angel Lanas; Corrado Blandizzi; Willem F Lems; Matthias Hermann; Richard H Hunt
Journal:  BMC Med       Date:  2015-03-19       Impact factor: 8.775

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.